Add:Room 301, Tianfu Innovation Center, Southern Section #846, Tianfu Avenue, Chengdu,Sichuan, China
R & D Centre
Add：Room E21, 5/F, Building B, Block 1, Northern Section #1480, High-tech Zone, Chengu, Sichuan, China
Your present location:
- Categories:R & D
- Time of issue:2020-12-16 14:47:27
New adenovirus vector technology:
In the development of new genetically engineered vaccine, and new biological drug and gene therapy of diseases, the adenovirus, as a drug carrier, has been highly concerned by the academia, and new drugs of adenovirus vectors continue to come to the market, along with active research in this filed. Adenovirus vector has become the preferred live vector drug of genetic engineering due to its extensive application, high security, excellent adaptability in large-scale production and other technical advantages. Among the global cases involving the development and application of live vector, adenovirus accounts for more than 26%. Farwits Biotechnology has developed the new adenovirus vector technology, namely, the fourth generation adenoviral vectors with small immunogenicity, stable property and large expression quantity, as well as superior performance, so the new drugs produced and expressed has more precise efficacy, greatly enhances the adaptability and safety, and becomes the best choice for vector vaccines and other drugs. By far, FarwitsBiotechnology has become the world's second company and the first Chinese enterprise to master this technology.
New baculovirus and yeast expression systems:
The genetically engineered vaccines and protein products successfully developed have an important sign, that is, the recombinant DNA technology can be used for successful expression of VLP (virus-like particles). Baculovirus and yeast have currently become the most efficient two systems for VLP expression and production. As the technology of VLP expression gradually matures, the bottlenecks of traditional vaccines in biotechnology field, including long development cycle, high costs, unstable product quality and obvious side effects, have been quickly broken. Especially, it opens up a new path in the research on the treatment means incapable of obtaining the vaccine through pathogen culture. By relying on its strong scientific research strength, FarwitsBiotechnology optimizes and makes innovation in foreign baculovirus and yeast expression system, so its system has been much better than the international similar reagents in development efficiency, production flexibility and richness of expression. With the use of the above system, the company has successfully developed a series of domestic leading products, such as HFMD bivalent vaccine, HPV (cervical cancer) 9-valent vaccine, HCV (hepatitis C) vaccine, norovirus vaccine, HFMD diagnostic kit and hepatitis C diagnostic kit.
Development of Biological Products Production Process:
Farwits Biotechnology establishes a development team of biological products production process that consists of a wealth of internationally renowned vaccine expert and domestic professional technical personnel with rich experience and senior qualifications as well as senior engineers. The team overcomes a number of influential technical problems in domestic vaccine industry, such as rabies virus vero cell DNA residues, and efficient production of live vector vaccine under the existing reactor conditions. Meanwhile, it has independently launched the most powerful therapeutic hepatitis B vaccine project. In other areas of biological products, like blood products extraction, recombinant protein synthesis and antibody kit design, it has leading unique and innovative techniques, and provides guidance and assistance for the pilot plant test and production of all types of biotech products.
Drug registration and technical service of clinical research:
The clinical research service team was established prior to the foundation of Farwits Biotechnology. It is composed of senior clinical researchers, with the business of professional program design and implementation of clinical research at the core. It covers new drugs I ~ IV phase clinical test, clinical validation of medical device, new drug project approval and survey, third-party auditing, data management and statistical analysis, medical document writing, drug registration application, post-market clinical re-evaluation and other outsourcing services of clinical evaluation. The team has conducted clinical studies in such fields as tumor, anti-infection, angiocarpy, digestion, respiration, blood, obstetrics and gynecology, endocrinology, traumatology and orthopedics. Meanwhile, the clinical team has maintained close cooperation of scientific research with more than 30 GCP institutions. In addition, it is able to design research programs for enterprises in line with the national regulations, with sound project quality management and operational experience, obtain high-quality clinical research data, and assist pharmaceutical enterprises to find the shortcut approach to the launch of pharmaceutical products.